肿瘤89Zr-pembrolizumab 摄取与肿瘤反应(P 趋势 = 0.014)和无进展(P = 0.0025)和总生存期(P = 0.026)相关。89Zr-pembrolizumab 5 mg 的摄取在脾脏中最高,平均 SUV 平均值为 5.8(±SD 1.8)。在 Waldeyer 环、正常淋巴结和炎症部位也有89Zr-pembrolizumab 摄取。 结论:89Zr-pembrolizumab 在肿瘤病变中的摄取与...
最佳剂量为 5 mg pembrolizumab,PET 扫描的最佳时间点为第 7 天。黑色素瘤和 NSCLC 之间的肿瘤 SUV max 没有差异(4.9 和 6.5,P = 0.49)。肿瘤 89 Zr-pembrolizumab 摄取与肿瘤反应(P 趋势 = 0.014)和无进展(P = 0.0025)和总生存期(P = 0.026)相关。 89 Zr-pembrolizumab 5 mg 的摄取在脾脏中最高,...
11,12 In part B, PET imaging was carried out at the optimal pembrolizumab dose and day of imaging as determined in part A. When feasible, a tumor biopsy was carried out in part B shortly after the day 7 PET scan. Participation in the 89Zr-pembrolizumab PET imaging study was followed ...
89 Zr-pembrolizumab tumor uptake was calculated as maximum standardized uptake value (SUV max ) and expressed as geometric mean. Normal organ uptake was calculated as SUV mean , and expressed as a mean. Tumor response was assessed according to (i)RECIST v1.1. RESULTS :Eighteen patients, 11 ...
89Zr-N-sucDf-pembrolizumabCynomolgus monkeysMesenteric lymph nodesSpleen and tonsilsStandardized uptake values (SUVmean)Purpose Programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) are the targets for immunotherapy in many cancer types. Although PD-1 blockade has therapeutic effects, the...
This study aims to evaluate the biodistribution of Zirconium-89 ( Zr)-labeled pembrolizumab, a humanized IgG4 kappa monoclonal antibody targeting PD-1, in healthy cynomolgus monkeys as a translational model of tracking PD-1-positive immune cells. Procedures Pembrolizumab was conjugated with the ...